CD44 and melanoma: Recently, Zhao et al. [26] demonstrated that vaccination with CSCs (CD133+CD44+) isolated from B16F10 murine melanoma cells specifically targeted B16F10-CSCs, reducing tumor growth and extending mouse survival.